Sanofi flashes blockbuster arsenal

Two highly anticipated drugs, each with sales expected to surpass the $1 billion mark in the coming years, are among six new products to make their first regulatory appearance in Australia – and they both belong to Sanofi.

This includes Sanofi’s BTK inhibitor tolebrutinib which has been granted the priority review pathway in multiple sclerosis plus the company’s efanesoctocog alfa, known as Altuviiio overseas, which has received an orphan drug designation for the treatment of haemophilia A.

Altuviiio is the first once-weekly factor VIII replacement intravenous infusion therapy for haemophilia A and is expected to reap US$1.77 billion in sales in 2029, according to analysts at Clarivate.